Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D | P25100 | 4/20 | 0.60 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.60 |
| ▸ | ADRA1B | P35368 | 4/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | DRD2 | P14416 | 1/20 | 0.55 |
| ▸ | HTR1A | P08908 | 1/20 | 0.55 |
| ▸ | HTR7 | P34969 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5654887 | 0.94 | ADRA1A (0.66) | ADRA1DADRA1AADRA1BMAPK1KMT2A | |
| SCHEMBL5656389 | 0.92 | ADRA1D (0.65) | ADRA1DADRA1AADRA1BUSP2LMNA | |
| SCHEMBL5654298 | 0.90 | ADORA2B (0.51) | ADRA1DADRA1AADRA1BMAPTKMT2A | |
| SCHEMBL5666368 | 0.90 | KMT2A (0.51) | ADRA1DADRA1AADRA1BUSP2LMNA | |
| SCHEMBL14457596 | 0.90 | HTR1A (0.50) | ADRA1DADRA1AADRA1BMAPK1TDP1 | |
| SCHEMBL5657858 | 0.89 | PKM (0.63) | LMNAMAPTKMT2AALDH1A1 | |
| SCHEMBL14457589 | 0.87 | HTR7 (0.47) | ADRA1DADRA1AADRA1BMAPK1TDP1 | |
| SCHEMBL14457602 | 0.87 | MEN1 (0.51) | ADRA1DADRA1AADRA1BMAPTKMT2A | |
| SCHEMBL5657841 | 0.86 | HTR1A (0.55) | LMNAMAPTKMT2ATDP1HTR1A | |
| SCHEMBL5655841 | 0.86 | ADRA1A (0.71) | ADRA1DADRA1AADRA1BKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7238693-B2 | Aryl carbamate derivatives, preparation and use thereof | CEREP (FR) | 2007-07-03 | — | — | US | disclosed |
| US-7238693-B2 | Aryl carbamate derivatives, preparation and use thereof | CEREP (FR) | 2007-07-03 | — | — | US | disclosed |
| US-7238693-B2 | Aryl carbamate derivatives, preparation and use thereof | CEREP (FR) | 2007-07-03 | — | — | US | disclosed |
| US-20040058933-A1 | Aryl carbamate derivatives, preperation and use thereof | CEREP (FR) | 2004-03-25 | — | — | US | disclosed |
| EP-1362041-A1 | ARYL CARBAMATE DERIVATIVES, PREPARATION AND USE THEREOF | Cerep (FR) | 2003-11-19 | — | — | EP | disclosed |
| WO-2002068399-A1 | ARYL CARBAMATE DERIVATIVES, PREPARATION AND USE THEREOF | CEREP (FR) | 2002-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058933-A1 | Aryl carbamate derivatives, preperation and use thereof | HTR4, HTR5A, HTR3C | ADRA1D 265/4885ADRA1A 294/4885ADRA1B 202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.